Ajanta Pharma USA Inc Ranolazine Extended-Release Tablets, 1000 mg, 60-count bottle recall: Failed Dissolution Specifications: below specification
Failed Dissolution Specifications: below specification
The hazard: Potency, impurity or stability failure
This is a specification failure: testing showed the product does not match what the label promises.
What the notice says: Failed Dissolution Specifications: below specification
Why it matters: The product failed a specification test: it may contain more or less active ingredient than the label states, carry an impurity, or degrade before its expiry date. A sub-potent dose can leave a condition untreated; a super-potent one can cause an overdose.
Symptoms and when to call a doctor
The risk depends entirely on the drug. For a medicine where dose matters closely — a blood thinner, an anti-epileptic, a thyroid or heart medicine, insulin — talk to your prescriber before changing anything. Seek urgent care if you have symptoms that suggest too much drug, or if the condition the medicine controls starts breaking through.
This page is general information, not medical advice. If you feel unwell, a clinician who can see you is the only person able to judge your case.
Recall details
- Recall number
- D-0010-2027
- Published
- October 7, 2026
- Risk level
- Class II
- Status
- Ongoing
- Issued by
- U.S. Food and Drug Administration
- Brand
- Ajanta Pharma USA Inc
- Product type
- Prescription & OTC drugs
- Distribution
- Nationwide
- Made in
- United States
- Lot / code info
- Lot: DJ25134, Exp 11/30/2028
Products covered by this recall
Ranolazine Extended-Release Tablets, 1000 mg, 60-count bottle, Rx Only, Marketed by: Ajanta Pharma USA Inc., Bridgewater, NJ 08807. NDC: 27241-126-02
Check your product
The notice names 10 codes you can read straight off the package. Type the one printed on yours and the list below narrows to it.
Lot or batch code
Usually ink-stamped near the seam, the cap or the bottom of the pack.
- DJ25134
- Exp 11
- 30
- 2028
Best-by / use-by date
Printed beside the lot code, not on the price sticker.
- 11
- 30
- 2028
NDC number
On the carton and again on the bottle or blister label.
- 27241-126-02
Package size
Match the net weight or the piece count on the front of the pack.
- 1000 mg
- 60 count
Codes are lifted verbatim from the FDA — Drug enforcement notice. A code that is missing here may still be covered — the official notice is the complete list.
What to do about Potency
Ajanta Pharma USA Inc — This is a specification failure: testing showed the product does not match what the label promises.
- Check the lot number on your pack against the codes listed above before you do anything else.
- Keep the carton and the leaflet — the lot number is usually printed only on the outer pack.
- Report any change in how the medicine is working to FDA MedWatch, which is where most of these signals originate.
- Do not stop a prescription on your own. For most conditions an uncertain dose is safer than no dose while you get advice.
Refunds and replacements
With medicines, a replacement supply matters more than cash, and that is what pharmacies are set up to provide.
- Ask the dispensing pharmacy for a like-for-like replacement from an unaffected lot. This is the fastest route and usually costs nothing.
- For a mail-order or online pharmacy, use the recall line listed on this page rather than the general support queue.
- If the recall voided a fill you had already paid for, your insurer will normally authorise a replacement ahead of schedule. Quote the recall number.
- If you paid out of pocket, ask for a refund of the co-pay or purchase price and keep the receipt the pharmacy issues.
Company contact: Ajanta Pharma USA Inc — 400 Crossing Blvd Ste 102, Bridgewater, NJ, 08807-2863
The official notice
This page summarises a notice published by U.S. Food and Drug Administration. The agency notice is the authoritative version — read it before you act, and treat it as the final word if anything here looks different.
Open the FDA — Drug enforcement record U.S. Food and Drug Administration recalls
Questions people ask about this recall
Why was Ajanta Pharma USA Inc prescription & otc drugs recalled?
Failed Dissolution Specifications: below specification Failed Dissolution Specifications: below specification
How do I know if I have the recalled product?
Match the codes printed on your package against the notice: lot code DJ25134, Exp 11, 30; best-by date 11 or 30. If the code on your package is not on that list, your unit is outside the recall.
What should I do with it right now?
Check the lot number on your pack against the codes listed above before you do anything else.
Can I get my money back?
Ask the dispensing pharmacy for a like-for-like replacement from an unaffected lot. This is the fastest route and usually costs nothing.
Where was the recalled product sold?
It was distributed nationwide.
Related recalls
-
Class III · last month
Ajanta Pharma USA Inc Fluphenazine Hydrochloride Tablets, USP, 1mg, 100-count bottles recall: Failed impurities/degradation specifications: (OOS) for Organic Impurities
Failed impurities/degradation specifications: (OOS) for Organic Impurities by HPLC (Impurity-A) during testing at the 18 months long term stability…
-
Class II · 4 months ago
Ajanta Pharma USA Inc Fenofibrate Capsules, USP 200 mg recall: CGMP Deviations
CGMP Deviations
-
Class II · 4 months ago
Ajanta Pharma USA Inc Aripiprazole Tablets USP recall: Product Mix-Up: A bottle containing Voriconazole Tablets 50 mg was labelled
Product Mix-Up: A bottle containing Voriconazole Tablets 50 mg was labelled and distributed as Aripiprazole Tablets USP 30 mg.
-
Class II · 6 months ago
Ajanta Pharma Ltd. Duloxetine Delayed-Release Capsules, 30 mg recall: CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA
CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term…
-
Class II · 6 months ago
Ajanta Pharma Ltd. Duloxetine Delayed-Release Capsules, 20 mg recall: CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA
CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term…
-
Class II · 6 months ago
Ajanta Pharma Ltd. Duloxetine Delayed-Release Capsules, 60 mg recall: CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA
CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term…